Rocket Pharmaceuticals Inc Stock Nasdaq
Stocks
US45780V1026
Biotechnology & Medical Research
| Market Cap | 424M 365M 342M 313M 589M 40.5B 591M 4.06B 1.58B 20.44B 1.59B 1.56B 67.79B | P/E 2026 * |
-13.7x | P/E 2027 * | -2.84x |
|---|---|---|---|---|---|
| Enterprise Value | 103M 88.87M 83.32M 76.06M 143M 9.86B 144M 989M 386M 4.98B 387M 379M 16.5B | EV / Sales 2026 * |
93.1x | EV / Sales 2027 * | 7.72x |
| Free-Float |
96.76% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : Rocket Pharmaceuticals Inc
| 1 day | -0.55% |
| Manager | Title | Age | Since |
|---|---|---|---|
Gaurav D. Shah
CEO | Chief Executive Officer | 51 | 2018-01-03 |
Martin Wilson
DFI | Director of Finance/CFO | 49 | 2025-09-07 |
Syed Rizvi
CTO | Chief Tech/Sci/R&D Officer | 59 | 2025-08-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Gaurav D. Shah
BRD | Director/Board Member | 51 | 2018-01-03 |
Rod Wong
CHM | Chairman | 49 | 2017-12-31 |
David Southwell
BRD | Director/Board Member | 65 | 2017-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.55% | +8.16% | - | - | 424M | |
| -1.59% | -3.35% | +52.37% | +91.62% | 69.54B | |
| -1.34% | -0.75% | +48.21% | +92.23% | 64.97B | |
| +0.30% | -0.69% | +52.56% | +9.51% | 26.51B | |
| -2.35% | -5.75% | -12.90% | +436.87% | 25.89B | |
| -8.37% | -12.43% | +2.08% | -18.39% | 25.64B | |
| -0.96% | +10.36% | +283.06% | +429.04% | 20.22B | |
| -0.51% | +0.23% | +35.77% | -19.61% | 19.98B | |
| -1.91% | -4.37% | +13.28% | +557.93% | 15.69B | |
| -1.47% | +0.68% | +45.51% | +142.00% | 13.49B | |
| Average | -1.87% | -1.93% | +57.77% | +191.24% | 31.33B | |
| Weighted average by Cap. | -1.93% | -1.50% | +53.73% | +150.41% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.11M 954K 895K 817K 1.54M 106M 1.54M 10.61M 4.14M 53.42M 4.16M 4.07M 177M | 11.46M 9.88M 9.26M 8.45M 15.92M 1.1B 15.98M 110M 42.87M 553M 43.03M 42.1M 1.83B |
| Net income | -17.76M -15.3M -14.35M -13.1M -24.67M -1.7B -24.75M -170M -66.42M -857M -66.68M -65.23M -2.84B | -182M -157M -147M -135M -254M -17.44B -254M -1.75B -682M -8.8B -685M -670M -29.19B |
| Net Debt | -321M -276M -259M -236M -445M -30.64B -447M -3.07B -1.2B -15.47B -1.2B -1.18B -51.29B | -335M -289M -271M -247M -466M -32.04B -467M -3.21B -1.25B -16.17B -1.26B -1.23B -53.62B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
